Notice of Closed Meeting, 6562-6563 [2022-02388]
Download as PDF
<![CDATA[
6562
Federal Register / Vol. 87, No. 24 / Friday, February 4, 2022 / Notices
lotter on DSK11XQN23PROD with NOTICES1
(clinical and laboratory testing);
promote TB, MDR–TB, and TB/HIV
prevention and integration into existing
healthcare services; strengthen TB
surveillance and monitoring and
evaluation (M&E) and improve
collaboration and coordination between
TB and other programs, particularly HIV
and COVID–19. Funding amounts for
years 2–5 will be set at continuation.
DATES: The period for this award will be
September 30, 2022 through September
29, 2027.
FOR FURTHER INFORMATION CONTACT:
Amy Bailey, Center for Global Health,
Centers for Disease Control and
Prevention, 5th/Floor Tung Shing
Building, No 2, Ngo Quyen Street, Hoan
Kiem District Hanoi, Vietnam,
Telephone: 800–232–6348, email: fue8@
cdc.gov.
SUPPLEMENTARY INFORMATION: The
single-source award will contribute to
enhancing early and universal access to
high quality prevention, diagnosis, and
treatment services for TB, MDR–TB, and
TB/HIV with the goal of ending TB in
Vietnam by 2030.
The NLH/NTP is in a unique position
to conduct this work as it is mandated
by Vietnam Ministry of Health (MoH)
with oversight and implementation of
TB prevention and control activities in
Vietnam. The NLH is the leading
tertiary hospital in charge of
examination and treatment of TB and
lung diseases and steering TB and lung
disease prevention and control activities
throughout the country.
Summary of the Award
Recipient: National Lung Hospital
(NLH)/National Tuberculosis Program
(NTP).
Purpose of the Award: The purpose of
this award is to support high quality TB,
MDR–TB, and TB/HIV programs to
strengthen and expand TB and MDR–TB
quality-assured diagnostic capacity
(clinical and laboratory testing);
promote TB, MDR–TB, and TB/HIV
prevention and integration into existing
healthcare services; strengthen TB
surveillance and M&E and improve
collaboration and coordination between
TB and other programs, particularly HIV
and COVID–19.
Amount of Award: The approximate
year 1 funding amount will be
$1,500,000 in Federal Fiscal Year (FYY)
2022 funds, subject to the availability of
funds. Funding amounts for years 2–5
will be set at continuation.
Authority: This program is authorized
under Public Law 108–25 (the United
States Leadership Against HIV AIDS,
Tuberculosis and Malaria Act of 2003).
Period of Performance: September 30,
2022 through September 29, 2027.
VerDate Sep<11>2014
18:50 Feb 03, 2022
Jkt 256001
Dated: February 1, 2022.
Terrance Perry,
Chief Grants Management Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2022–02412 Filed 2–3–22; 8:45 am]
BILLING CODE 4163–18–P
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–02381 Filed 2–3–22; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Notice of Closed Meeting
Centers for Disease Control and
Prevention
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP);
SIP22–001, Process, Outcome, and Cost
Evaluation of Free Sunscreen
Dispensers in Outdoor Community
Settings.
Date: April 26, 2022.
Time: 11:00 a.m.–6:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Jaya
Raman Ph.D., Scientific Review Officer,
National Center for Chronic Disease
Prevention and Health Promotion, CDC,
4770 Buford Highway, Mailstop S107–
B, Atlanta, Georgia 30341, Telephone:
(770) 488–6511, Email: JRaman@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP):
RFA–PS–22–001, Implementing Preexposure Prophylaxis for HIV
Prevention in Syringe Service Programs;
RFA–PS–22–002, Implementation
Research on Telehealth Strategies to
Support Retention in Care and
Treatment among Antiretroviral
Therapy (ART) Patients and Preexposure Prophylaxis (PrEP) Clients;
and RFA–PS–22–004, Understanding
HIV/STD Risk and Enhancing PrEP
Implementation Messaging in a Diverse
Community-Based Sample of Gay,
Bisexual, and Other Men Who Have Sex
with Men in a Transformational Era.
Date: March 30, 2022.
Time: 10:00 a.m.–5:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, National
Center for HIV, Viral Hepatitis, STD,
and TB Prevention, 1600 Clifton Road,
NE, Mailstop US8–1, Atlanta, Georgia
E:\FR\FM\04FEN1.SGM
04FEN1
Federal Register / Vol. 87, No. 24 / Friday, February 4, 2022 / Notices
30329, (404) 718–8833, GAnderson@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–02388 Filed 2–3–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Announcement of Requirements and
Registration for the REACH Lark
Galloway-Gilliam Nomination for
Advancing Health Equity Challenge
(REACH Lark Award Challenge)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), located
within the Department of Health and
Human Services (HHS), announces the
2022 Racial and Ethnic Approaches to
Community Health (REACH) Lark
Galloway-Gilliam for Advancing Health
Equity Award Challenge (REACH Lark
Award Challenge). This biennial
challenge was established in 2019 to
recognize extraordinary individuals,
organizations, or community coalitions
associated with the REACH program
whose work has contributed to the
implementation of culturally tailored
interventions that advance health
equity, reduce health disparities, and
increase community engagement to
address preventable risk factors (e.g.,
tobacco use, poor nutrition, physical
inactivity, and inadequate access to
clinical services).
DATES: The Challenge will accept
applications from February 7, 2022
through March 18, 2022.
Award Approving Official: Rochelle P.
Walensky, MD, MPH, Director, Centers
for Disease Control and Prevention, and
Administrator, Agency for Toxic
Substances and Disease Registry.
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:50 Feb 03, 2022
Jkt 256001
FOR FURTHER INFORMATION CONTACT:
Kristy Mugavero, National Center for
Chronic Disease Prevention and Health
Promotion, Centers for Disease Control
and Prevention, 4770 Buford Hwy. NE,
Mailstop S107–5, Atlanta, GA 30341,
Telephone: 770–488–2047, Email:
dnpaopolicy@cdc.gov.
SUPPLEMENTARY INFORMATION: Racial and
ethnic disparities in health remain
pervasive across the United States. CDC
administers REACH, a national program
that provides funding to state and local
health departments, tribes, universities,
and community-based organizations.
Since REACH was established in 1999,
the program has demonstrated success
in addressing these disparities and
promoting health equity by engaging
with diverse communities and
implementing culturally tailored
interventions. For more information
about the REACH program, visit https://
www.cdc.gov/nccdphp/dnpao/statelocal-programs/reach/index.htm.
The intent of this challenge is to
recognize individuals and organizations
or community coalitions associated with
the REACH program that meaningfully
assisted with and carried out culturally
tailored interventions that advance
health equity, reduce health disparities,
and increase community engagement to
address preventable risk factors (e.g.,
tobacco use, poor nutrition, physical
inactivity, and inadequate access to
clinical services) in populations or
groups disproportionately affected by
chronic disease; specifically, African
American/Black, American Indian or
Alaska Native, Asian, Hispanic or
Latino, and Native Hawaiian or other
Pacific Islander persons. To support the
science and practice of improving
health equity, this challenge can help
further the goals of the REACH program
by documenting and further
disseminating the innovative or unique
interventions employed by individuals,
organizations or community coalitions
applying or nominated for this award.
Subject of Challenge Competition:
The challenge is authorized by Public
Law 111–358, the America Creating
Opportunities to Meaningfully Promote
Excellence in Technology, Education
and Science Reauthorization Act of
2010 (COMPETES Act).
The ‘‘applicant’’ refers to each
individual, organization, or community
coalition who submits an application or
nomination. The ‘‘nominee’’ refers to
each individual or organization/
community coalition who is nominated,
whether self-nominated or nominated
by a separate applicant.
Applicants will be asked to respond
to a series of questions related to how
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
6563
the nominee assisted with and carried
out culturally tailored interventions to
advance health equity, reduce health
disparities, and increase community
engagement to address preventable risk
factors (e.g., tobacco use, poor nutrition,
physical inactivity, and inadequate
access to clinical services) in
populations or groups
disproportionately affected by chronic
disease; specifically African American/
Black, American Indian or Alaska
Native, Asian, Hispanic or Latino, and
Native Hawaiian or other Pacific
Islander persons.
Eligibility Rules for Participating in the
Challenge
The REACH Lark Award Challenge is
open to the public. To be eligible for
this award, nominees must meet the
following eligibility requirements:
(1) Shall have completed the
application (for self-nominees) or have
had an application submitted on their
behalf (for those nominate by others) for
the competition under the rules
promulgated by HHS/CDC;
(2) Shall have complied with all the
requirements under this section and
satisfy one of the following
requirements:
a. Be a currently or previously funded
CDC REACH recipient that has not
previously received the REACH Lark
Award in any year; or
b. Be a technical assistance provider
to a former or current REACH recipient
(current and past REACH recipients can
be found at: https://www.cdc.gov/
nccdphp/dnpao/state-local-programs/
reach/index.htm); or
c. Be a partner organization, part of a
partner network, or coalition members
that collaborated on REACH-related
work with a current or previously
funded REACH recipient;
(3) Shall not have been a REACH Lark
Award Challenge recipient in any
previous year;
(4) Shall be either:
a. A U.S. citizen or legal permanent
resident, eighteen years of age or older,
if the nominee is an individual or group
of individuals; or
b. Incorporated in and maintain a
primary place of business in the United
States, if the nominee is an entity;
where the United States means a state,
the District of Columbia, the
Commonwealth of Puerto Rico, and any
other territory or possession of the
United States;
(5) Shall not be a federal entity or
federal employee acting within the
scope of their employment;
(6) Shall not be an employee of or
contractor of CDC;
E:\FR\FM\04FEN1.SGM
04FEN1
]]>Agencies
[Federal Register Volume 87, Number 24 (Friday, February 4, 2022)]
[Notices]
[Pages 6562-6563]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-02388]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended, and the Determination of the Director, Strategic
Business Initiatives Unit, Office of the Chief Operating Officer, CDC,
pursuant to Public Law 92-463. The grant applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP): RFA-PS-22-001, Implementing Pre-
exposure Prophylaxis for HIV Prevention in Syringe Service Programs;
RFA-PS-22-002, Implementation Research on Telehealth Strategies to
Support Retention in Care and Treatment among Antiretroviral Therapy
(ART) Patients and Pre-exposure Prophylaxis (PrEP) Clients; and RFA-PS-
22-004, Understanding HIV/STD Risk and Enhancing PrEP Implementation
Messaging in a Diverse Community-Based Sample of Gay, Bisexual, and
Other Men Who Have Sex with Men in a Transformational Era.
Date: March 30, 2022.
Time: 10:00 a.m.-5:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, National Center for HIV, Viral
Hepatitis, STD, and TB Prevention, 1600 Clifton Road, NE, Mailstop US8-
1, Atlanta, Georgia
[[Page 6563]]
30329, (404) 718-8833, [email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-02388 Filed 2-3-22; 8:45 am]
BILLING CODE 4163-18-P
